CARLSBAD, Calif., June 17, 2013 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced the launch of Epi5 Episomal iPSC Reprogramming Vectors, the world's first product to be fully commercialized based on technology that won its developers a Nobel Prize in 2012 for the ability to easily reprogram adult human cells into an early embryonic state.
Scientists use induced pluripotent stem cell (iPSC) technology to create iPSCs from patient-derived adult somatic cells. The iPSCs can then be differentiated into many cell types, such as neurons and hepatocytes, to be studied in the lab. The ease-of-use and reprogramming efficiency of Epi5 Episomal iPSC Reprogramming Vectors helps accelerate the process for applications in basic research and pre-clinical studies.
"You can give rise to iPSCs at a high efficiency rate by using the Epi5 Episomal iPSC Reprogramming Kit," said Dr. Keisuke Okita, Lecturer, Center for iPS Cell Research and Application, Kyoto University, who helped developed the Nobel Prize-winning technology with Dr. Shinya Yamanaka. "We are delighted to see that Life Technologies is taking the lead to make it available and we hope that many researchers will use it to advance research in areas such as pathology, drug discovery and stem cell biology."
While other reprogramming vectors have been developed in Dr. Yamanaka's lab, none has ever been commercially available. Epi5 Episomal iPSC Reprogramming Vectors is the result of a global, non-exclusive license agreement Life Technologies signed last year with iPS Academia Japan for its iPSC patent portfolio. The license expands Life's range of products and services and underscores the company's commitment to provide the most innovative tools to the iPSC community.
"The ability to easily generate iPS cells from patient-derived adult somatic cells allows researchers to study the genetics behind specific diseases," said Chris Armstrong, Ph.D., General Manager and Vice President of Primary and Stem Cell Systems at Life Technologies. "This is a crucial step toward development of new potential treatments and one that we are committed to supporting with leading technologies."
Epi5 Episomal iPSC Reprogramming Vectors is For Research Use Only, not intended for diagnostic purposes.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents and licenses that span the entire biological spectrum -- scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012.
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Life Technologies Contact
SOURCE Life Technologies Corporation